Can-Fite Plans Phase III For Namodenoson, Despite Liver Cancer Trial Failure
Executive Summary
Patients with the most severe type of disease were all randomized to treatment with the study drug, which may have had a negative impact on outcome, the Israeli company suggested.
You may also be interested in...
Merck's Keytruda Loss In Liver Cancer Could Be Gain For Rivals
The drug demonstrates improvements in overall survival and progression-free survival, but not enough for success in KEYNOTE-240.
Keeping Track: FDA's Review Actions Carry On During Shutdown
The latest drug development news and highlights from our US FDA Performance Tracker.
First In 10 Years, But Lenvima's First-Line Liver Label Could Be Challenged Soon
Eisai and Merck won the first US FDA approval in 10 years for a first-line hepatocellular carcinoma treatment with Lenvima, but challengers are on the horizon. The companies' recent partnership and plans for combination therapy with Keytruda may defend the drug's standing in liver cancer.